公开(公告)号：US11884715B2

公开(公告)日：2024-01-30

申请号：US16924473

申请日：2020-07-09

申请人： Keros Therapeutics, Inc.

发明人： Jasbir S. Seehra ,  Jennifer Lachey

IPC分类号： A61K38/17 ,  C07K14/47 ,  C07K14/71 ,  C07K14/705 ,  A61P21/00 ,  A61P19/00 ,  C07K14/04 ,  A61K38/00

CPC分类号： C07K14/705 ,  A61K38/1709 ,  A61K38/179 ,  A61P19/00 ,  A61P21/00 ,  C07K14/04 ,  C07K14/71 ,  A61K38/00 ,  C07K2317/52

摘要： The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and/or pulmonary hypertension.

公开(公告)号：US4812559A

公开(公告)日：1989-03-14

申请号：US28826

申请日：1987-03-23

申请人： Ronald W. Ellis ,  Paul M. Keller ,  Robert S. Lowe ,  Andrew J. Davison

发明人： Ronald W. Ellis ,  Paul M. Keller ,  Robert S. Lowe ,  Andrew J. Davison

IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K39/25 ,  C07H21/04 ,  C07K14/00 ,  C07K14/04 ,  C12N1/00 ,  C12N5/00 ,  C12N5/10 ,  C12N15/00 ,  C12N15/38 ,  C12P21/02 ,  C12R1/125 ,  C12R1/19 ,  C12R1/865 ,  C12R1/91 ,  C07H15/12

CPC分类号： A61K39/25 ,  A61K39/12 ,  C07K14/005 ,  A61K39/00 ,  C12N2710/16722 ,  C12N2710/16734 ,  Y10S930/224

摘要： A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. This gene can hybrid select messenger RNA which encodes and expresses a protein which reacts with human convalescent zoster sera and with polyclonal monospecific antisera which neutralize viral infectivity. These proteins are useful for the preparation of a vaccine for VZV.

摘要翻译： 通过DNA序列分析鉴定了编码免疫原性外表面病毒蛋白的水痘带状疱疹病毒（VZV）基因。 该基因可以杂交选择信使RNA，其编码和表达与人类恢复带状疱疹血清反应的蛋白质，以及中和病毒感染性的多克隆单特异性抗血清。 这些蛋白质可用于制备VZV疫苗。

公开(公告)号：US11883507B2

公开(公告)日：2024-01-30

申请号：US17221162

申请日：2021-04-02

申请人： Friedrich Miescher Institute for Biomedical Research

发明人： Dominik Hartl ,  Josephine Juettner ,  Arnaud Krebs ,  Botond Roska ,  Dirk Schuebeler

IPC分类号： C12N5/00 ,  A61K48/00 ,  C07K14/04 ,  C12N15/86 ,  A61K41/00 ,  C12N15/85 ,  C12N15/864

CPC分类号： A61K48/0058 ,  A61K41/0057 ,  A61K48/0075 ,  C07K14/04 ,  C12N15/85 ,  C12N15/86 ,  C12N15/8645 ,  C12N2750/14143 ,  C12N2830/008

摘要： The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.

公开(公告)号：US20210290759A1

公开(公告)日：2021-09-23

申请号：US17216619

申请日：2021-03-29

申请人： BRAVOVAX CO., LTD

发明人： Ting MU ,  Ping ZHAO ,  Long XU ,  Yang XIAO ,  Jean-philippe JULIEN ,  Yue WU ,  Liang XIE ,  Xueting CHEN ,  Qi LIU ,  Charles Dwo Yuan SIA ,  Pele Choi Sing CHONG ,  Michel KLEIN ,  Linsen DU ,  Ke WU

IPC分类号： A61K39/25 ,  C07K14/04 ,  C07K14/255 ,  C12N15/86 ,  C12N15/70 ,  C12N15/62

摘要： A prokaryotic expression system or a recombinant adenovirus system is used to highly efficiently express VZV envelope gE glycoprotein and the flagellin fusion protein thereof. The produced recombinant gE protein, gE flagellin fusion protein and recombinant adenovirus vector, or composition thereof is used to immunize a mouse so as to promote the body to generate gE and VZV-specific antibody titer, as well as gE-specific and VZV-specific cell immunity.

公开(公告)号：US4686101A

公开(公告)日：1987-08-11

申请号：US762001

申请日：1985-08-02

申请人： Ronald W. Ellis ,  Robert S. Lowe ,  Paul M. Keller ,  Andrew J. Davison

发明人： Ronald W. Ellis ,  Robert S. Lowe ,  Paul M. Keller ,  Andrew J. Davison

IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K39/25 ,  C07H21/04 ,  C07K14/00 ,  C07K14/04 ,  C12N1/00 ,  C12N5/00 ,  C12N5/10 ,  C12N15/00 ,  C12N15/38 ,  C12P21/02 ,  C12R1/125 ,  C12R1/19 ,  C12R1/865 ,  C12R1/91 ,  C07K13/00

CPC分类号： A61K39/25 ,  A61K39/12 ,  C07K14/005 ,  A61K39/00 ,  C12N2710/16722 ,  C12N2710/16734 ,  Y10S930/224

摘要： A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. This gene can hybrid select messenger RNA which encodes and expresses a protein which reacts with human canvalescent zoster sera and with polyclonal monospecific antisera which neutralize viral infectivity. These proteins are useful for the preparation of a vaccine for VZV.

公开(公告)号：US11236131B2

公开(公告)日：2022-02-01

申请号：US16366240

申请日：2019-03-27

申请人： The University of Birmingham

发明人： Mark Cobbold ,  David Millar

IPC分类号： C07K14/005 ,  A61K47/68 ,  A61K47/64 ,  A61K39/12 ,  C07K16/28 ,  C07K16/32 ,  A61K38/20 ,  A61K39/08 ,  A61K39/145 ,  A61K39/235 ,  A61K39/245 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00 ,  C12N7/00 ,  C07K16/30 ,  C07K14/74 ,  C07K14/11 ,  C07K14/045 ,  C07K14/05 ,  C07K14/12 ,  C07K14/04 ,  C07K14/095

摘要： The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.

公开(公告)号：US20210396761A1

公开(公告)日：2021-12-23

申请号：US17261501

申请日：2019-07-19

申请人： AICURIS GMBH & CO. KG ,  FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN-NURNBERG

发明人： Manfred MARSCHALL ,  Yves MULLER ,  Heinrich STICHT ,  Jutta EICHLER

IPC分类号： G01N33/68 ,  C07K14/05 ,  C07K14/04

摘要： The present invention generally provides for a novel NEC-targeted strategy for the development of antiherpesviral drugs as well as for a novel antiviral strategy targeting the viral-cellular nuclear egress complex (NEC) for a small molecule-based therapy or prophylaxis to control infections with human cytomegalovirus or other pathogenic viruses of the group of the Herpesviridae. Methods for screening agents/compounds/small molecules modulating/inhibiting the nuclear egress complex of Herpesviridae are provided as well. Specifically novel drug targets of the viral nuclear egress complex of viruses of the Herpesviridae are provided.

公开(公告)号：US6093535A

公开(公告)日：2000-07-25

申请号：US983045

申请日：1998-01-15

申请人： Chisato Mori ,  Rie Takahara ,  Juichiro Osame ,  Yasuyuki Gomi ,  Isao Fuke

发明人： Chisato Mori ,  Rie Takahara ,  Juichiro Osame ,  Yasuyuki Gomi ,  Isao Fuke

IPC分类号： A61K39/00 ,  C07K14/04 ,  C12N15/38 ,  C12Q1/70 ,  C07H21/04 ,  C12N7/00 ,  C12P19/34

CPC分类号： C07K14/005 ,  C12Q1/701 ,  A61K39/00 ,  C12N2710/16722

摘要： Disclosed is a method for exact identification of the attenuated varicella virus Oka strain or a strain derived therefrom capable of functioning as an attenuated varicella live vaccine virus, which comprises analyzing the difference in the genomic DNA and fragments thereof between the Oka strain and a sample varicella strain, and determining whether or not a sample strain satisfies all of the following eight characteristics: the sizes of the HpaI-K fragment and the EcoRI-P fragment; the size of R2-487 region of Gene14 and the analysis by PCR-SSCP; the sizes of the restriction fragments obtained by digesting the R2-1764 fragment with AccIII; the absence or presence of a PstI cleavage site; the homology of the amino acid sequences coded by R2-487 coding region; and the homology of the amino acid sequences coded by the coding region of VZV Gene14. The method of the present invention is extremely useful for the quality control and quality assurance of attenuated varicella live vaccines. Also disclosed are an isolated virus strain which is substantially the same virus strain as identified by the above method; an attenuated varicella virus live vaccine comprising the same virus strain as identified by the above method; an attenuated varicella virus Oka strain antigen; and a pair of primers which are advantageously, effectively usable in the above method.

摘要翻译： PCT No.PCT / JP97 / 01646 Sec。 371日期1998年1月15日 102（e）日期1998年1月15日PCT提交1997年5月15日PCT公布。 公开号WO97 / 43420 PCT 日期1997年11月20日公开是一种精确鉴定减毒水痘病毒Oka菌株或由其衍生的能够作为减毒水痘活疫苗病毒的菌株的方法，其中包括分析Oka基因组DNA及其片段之间的差异 菌株和样本水痘菌株，并确定样品菌株是否满足以下八个特征：HpaI-K片段和EcoRI-P片段的大小; Gene14的R2-487区域的大小和通过PCR-SSCP的分析; 通过用AccIII消化R2-1764片段获得的限制性片段的大小; 不存在或存在PstI切割位点; 由R2-487编码区编码的氨基酸序列的同源性; 和由VZV Gene14的编码区编码的氨基酸序列的同源性。 本发明的方法对于减毒水痘活疫苗的质量控制和质量保证是非常有用的。 还公开了分离的病毒株，其通过上述方法鉴定为基本上相同的病毒株; 包含由上述方法鉴定的相同病毒株的减毒水痘病毒活疫苗; 减毒水痘病毒Oka株抗原; 以及有利地在上述方法中有效使用的一对引物。

公开(公告)号：US5789232A

公开(公告)日：1998-08-04

申请号：US750742

申请日：1996-12-20

申请人： Klaus-Dieter Nothacker

发明人： Klaus-Dieter Nothacker

IPC分类号： A61K39/12 ,  A61K39/165 ,  A61K39/25 ,  C07K1/14 ,  C07K14/04 ,  C07K14/10 ,  C07K14/12 ,  C07K14/18 ,  G01N33/569 ,  G01N33/576 ,  C12N7/00

CPC分类号： A61K39/25 ,  A61K39/12 ,  C12N7/00 ,  G01N33/56983 ,  G01N33/56994 ,  G01N33/5768 ,  C12N2710/16634 ,  C12N2710/16651 ,  C12N2710/16734 ,  C12N2710/16751 ,  C12N2770/32434 ,  C12N2770/32451

摘要： The present invention relates to a process for preparing antigens of viral origin from infected animal cells and to the use thereof in enzyme-linked immunosorbent assays (ELISAs). The process utilizes homogenization, centrifugation and an alkaline glycene buffer.

摘要翻译： PCT No.PCT / EP95 / 02422 Sec。 371日期1996年12月20日第 102（e）日期1996年12月20日PCT提交1995年6月22日PCT公布。 公开号WO96 / 00083 日期1996年1月4日本发明涉及从感染的动物细胞制备病毒来源抗原的方法及其在酶联免疫吸附测定（ELISA）中的应用。 该方法利用均化，离心和碱性甘氨酸缓冲液。

公开(公告)号：US5556946A

公开(公告)日：1996-09-17

申请号：US386354

申请日：1995-02-08

申请人： Yukio Fujisawa ,  Shuji Hinuma ,  Aki Aono

发明人： Yukio Fujisawa ,  Shuji Hinuma ,  Aki Aono

IPC分类号： A61K39/00 ,  C07K14/035 ,  C07K14/04 ,  C07K14/16 ,  C07K14/55 ,  C07K16/08 ,  C12N1/21 ,  C12N15/26 ,  C12N15/38 ,  C12N15/48 ,  A61K38/20 ,  C12N15/62

CPC分类号： C07K16/08 ,  C07K14/005 ,  C07K14/55 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/40 ,  C07K2319/75 ,  C12N2710/16122 ,  C12N2710/16622 ,  C12N2710/16722 ,  C12N2740/16122 ,  C12N2740/16222

摘要： Disclosed are (1) a fused protein obtained by combining an antigen used for vaccine and a lymphokine by the application of gene engineering, (2) a recombinant DNA containing a nucleotide sequence coding for the above fused protein, (3) a transformant bearing the above recombinant DNA, (4) a method for producing the fused protein which comprises cultivating the above transformant, producing and accumulating the above fused protein in a culture, and collecting the fused protein, and (5) a hybrid protein obtained by chemically combining an antigen used for vaccine with a lymphokine. The resulting fused and hybrid proteins have strong immunogenicity.

摘要翻译： 公开的（1）通过应用基因工程将用于疫苗的抗原与淋巴因子组合而获得的融合蛋白，（2）含有编码上述融合蛋白的核苷酸序列的重组DNA，（3） （4）生产融合蛋白的方法，其包括培养上述转化体，在培养物中产生和积累上述融合蛋白，并收集融合蛋白，和（5）将化合物 用于具有淋巴因子的疫苗的抗原。 所得的融合蛋白和杂交蛋白具有很强的免疫原性。